- Home
- UGRO vs SNTI Comparison
UGRO vs SNTI Comparison
Compare UGRO & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UGRO | SNTI |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 53.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UGRO | SNTI |
|---|---|---|
| Price | $0.36 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 13.7M | 4.4M |
| Earning Date | 03-27-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $59,985,138.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.40 | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $1.15 |
| 52 Week High | $1.19 | $5.10 |
Technical Indicators
Market Signals| Indicator | UGRO | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 61.91 | 34.21 |
| Support Level | $0.27 | $1.15 |
| Resistance Level | $0.49 | $1.29 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 51.49 | 2.89 |
Price Performance
Historical ComparisonAbout UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.